Effectiveness and Safety of Dupilumab for the Treatment of Atopic Dermatitis in Adult Cohort: a Real‐Life Italian Tertiary Centre Experience

Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 7-10% of adults(1) . The systemic treatment for moderate-to-severe AD was limited, but a new biologic drug (Dupilumab) was recently approved. It is a fully human monoclonal antibody directed against the alpha-subunit of the interleukin-4-receptor, blocking signalling of both Th2-cytokines IL-4 and IL-13. The effectiveness and safety was demonstrated in clinical trials(2-4) , but these studies do not reflect conditions in daily practice.